Compare · BIIB vs CMRA
BIIB vs CMRA
Side-by-side comparison of Biogen Inc. (BIIB) and Comera Life Sciences Holdings Inc. (CMRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and CMRA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB carries a market cap of $36.89B.
- BIIB has hit the wire 10 times in the past 4 weeks while CMRA has been quiet.
- BIIB has more recent analyst coverage (25 ratings vs 0 for CMRA).
- Company
- Biogen Inc.
- Comera Life Sciences Holdings Inc.
- Price
- -
- -
- Market cap
- $36.89B
- -
- 1M return
- -1.67%
- -
- 1Y return
- +41.24%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 10
- 0
- Recent ratings
- 25
- 0
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Comera Life Sciences Holdings Inc.
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
Latest BIIB
- Clarity AD CSF Substudy Findings on Lecanemab Treatment and α-Synuclein Co-Pathology Presented at CTAD 2026
- New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026
- Biogen’s Diranersen Demonstrates Increasing Clinical Benefit at Two Years in Early Alzheimer’s Disease
- New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026
- FDA Approval for ZURZUVAE issued to BIOGEN
- LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Now Available in Japan for Patients with Early Alzheimer’s Disease
- SEC Form SCHEDULE 13G filed by Biogen Inc.
- ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure
- Stoke Therapeutics to Present at Upcoming Investor Conferences in November
- Head of Research Grogan Jane converted options into 695 shares and covered exercise/tax liability with 345 shares, increasing direct ownership by 9% to 4,408 units (SEC Form 4)
Latest CMRA
- SEC Form EFFECT filed by Comera Life Sciences Holdings Inc.
- SEC Form EFFECT filed by Comera Life Sciences Holdings Inc.
- SEC Form EFFECT filed by Comera Life Sciences Holdings Inc.
- SEC Form EFFECT filed by Comera Life Sciences Holdings Inc.
- SEC Form S-8 POS filed by Comera Life Sciences Holdings Inc.
- SEC Form S-8 POS filed by Comera Life Sciences Holdings Inc.
- SEC Form S-8 POS filed by Comera Life Sciences Holdings Inc.
- SEC Form POS AM filed by Comera Life Sciences Holdings Inc.
- SEC Form POS AM filed by Comera Life Sciences Holdings Inc.
- SEC Form POS AM filed by Comera Life Sciences Holdings Inc.